Share-based Payment Arrangement, Expense of Nabriva Therapeutics plc from 31 Dec 2015 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Nabriva Therapeutics plc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Jun 2023.
  • Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2023 was $98,000, a 71% decline year-over-year.
  • Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2023 was $1,730,000.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $1,967,000, a 40% decline from 2021.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2021 was $3,291,000, a 37% decline from 2020.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2020 was $5,219,000, unchanged from 2019.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Nabriva Therapeutics plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $1,730,000 $98,000 -$236,000 -71% 01 Apr 2023 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 $1,966,000 $999,000 -$1,000 -0.1% 01 Jan 2023 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 $1,967,000 $135,000 01 Oct 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
Q3 2022 $498,000 -$281,000 -36% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $334,000 01 Apr 2022 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 $1,000,000 +$79,000 +8.6% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q3 2021 $779,000 -$448,000 -37% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q1 2021 $921,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 $1,227,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2019 $1,907,000 +$663,000 +53% 01 Jan 2019 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q1 2018 $1,244,000 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1

Nabriva Therapeutics plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $1,967,000 -$1,324,000 -40% 01 Jan 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
2021 $3,291,000 -$1,928,000 -37% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
2020 $5,219,000 $0 0% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $5,219,000 +$65,000 +1.3% 01 Jan 2019 31 Dec 2019 10-K 17 Apr 2023 2022 FY
2018 $5,154,000 -$578,000 -10% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2021 2020 FY
2017 $5,732,000 +$3,187,000 +125% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $2,545,000 +$1,194,000 +88% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019 2018 FY
2015 $1,351,000 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.